Inventor

DAI MEIBI

CN12 patents

⚠️ This page may combine multiple inventors who share the name “DAI MEIBI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD

2 patents

US11008292B2May 18, 2021

FGFR4 inhibitor and preparation method and use thereof

GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD1 citations60

US11440903B2Sep 13, 2022

Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof

GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD0 citations50

WUXI LIFE FOUNTAIN BIOTECH CO LTD

2 patents

US11919898B2Mar 5, 2024

Crystal form of azaindole derivative and use thereof

WUXI LIFE FOUNTAIN BIOTECH CO LTD0 citations57

US12312347B2May 27, 2025

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

WUXI LIFE FOUNTAIN BIOTECH CO LTD0 citations47

NOVAONCO JS THERAPEUTICS CO LTD

2 patents

US12509440B2Dec 30, 2025

Fluorovinylbenzamide compound as PD-L1 immunomodulator

NOVAONCO JS THERAPEUTICS CO LTD0 citations53

US12152013B2Nov 26, 2024

Vinylpyridine carboxamide compound as PD-L1 immunomodulator

NOVAONCO JS THERAPEUTICS CO LTD0 citations42

MEDSHINE DISCOVERY INC

1 patent

US10519133B2Dec 31, 2019

Vinyl compounds as FGFR and VEGFR inhibitors

MEDSHINE DISCOVERY INC4 citations72

MERCK SHARP & DOHME

1 patent

US9834563B2Dec 5, 2017

Antidiabetic substituted heteroaryl compounds

MERCK SHARP & DOHME4 citations70

CGENETECH SUZHOU CHINA CO LTD

1 patent

US12378241B2Aug 5, 2025

Pyridine derivative as FGFR and VEGFR dual inhibitors

CGENETECH SUZHOU CHINA CO LTD1 citations61

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY

1 patent

US12297197B2May 13, 2025

Pyrazolopyridine compound as RET inhibitor and application thereof

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY1 citations58

CHONGQING PHARMACEUTICAL INDUSTRIAL RES INSTITUTE CO LTD

1 patent

US11161817B2Nov 2, 2021

Quinoline derivative and use thereof as tyrosine kinase inhibitor

CHONGQING PHARMACEUTICAL INDUSTRIAL RES INSTITUTE CO LTD1 citations54

HARBIN ZHENBAO PHARMACEUTICAL CO LTD

1 patent

US11078194B2Aug 3, 2021

Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor

HARBIN ZHENBAO PHARMACEUTICAL CO LTD0 citations45